Zenas BioPharma (ZBIO) Cash from Financing Activities (2023 - 2026)

Zenas BioPharma's Cash from Financing Activities history runs 4 years deep, the most recent figure standing at $433.5 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 437757.58% year-over-year to $433.5 million; the TTM figure through Mar 2026 stood at $648.7 million (up 56.81% YoY), while the FY2025 annual figure was $215.3 million, down 47.87% from the prior year.
• Cash from Financing Activities was $433.5 million for Q1 2026 at Zenas BioPharma, up from $140.8 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $433.5 million in Q1 2026 to a low of -$614000.0 in Q1 2024.
• Historically, Cash from Financing Activities has averaged $106.2 million across 4 years, with a median of $37.2 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities tumbled 99.03% in 2025, then surged 437757.58% in 2026.
• A 4-year view of Cash from Financing Activities shows it stood at $50000.0 in 2023, then surged by 3606.0% to $1.9 million in 2024, then surged by 7500.81% to $140.8 million in 2025, then jumped by 207.77% to $433.5 million in 2026.
• The last three Cash from Financing Activities figures came in at $433.5 million (Q1 2026), $140.8 million (Q4 2025), and $72.6 million (Q3 2025), per Business Quant data.